GENE ONLINE|News &
Opinion
Blog

2022-05-26| R&DTechnology

Stanford Touts Remote-Controllable CAR-T Cell Therapy

by Fujie Tham
Share To

Scientists from Stanford University designed a regulatable SNIP CAR-T platform that could circumvent toxicities associated with conventional CAR-T therapy. 

Chimeric antigen receptor (CAR) T cell therapy is T-cell modified to fit a patient’s cancer profile, then infused back into the patient’s body to fight cancer. It showed remarkable therapeutic activity in leukemia, and adults with lymphoma, while frequently tested on other cancers. Despite these promising results, severe and adverse events such as cytokine release syndrome (CRS) and neurotoxicity are common and can be fatal, causing the therapy to be reserved until other therapies fail. 

This research published on Cell presents SNIP CARs, a protease-based platform for regulating chimeric antigen receptor activity using a small molecule drug (grazoprevir) already approved by the FDA for hepatitis C treatment. “Previous efforts to create drug-regulatable CAR-T cells have yielded systems that are very finicky, or leaky,” Lead author Louai Labanieh said. “This is the first time we’ve been able to tune their activity so precisely.” 

Related article: Recounting 25 Years of Genetic and Human Diversity Discovery With deCODE Founder Kari Stefansson

 

Controlling CAR-T Cells Activity to Increase Effectiveness

 

By incorporating a molecular switch that turns on only when an oral medicine is supplied, the team hopes to address CAR-T therapy’s limited window to modulate cell dosage and activity when toxicity occurs. 

In an induced lethal toxicity mouse model, mice that were treated with the SNIP CAR-T cells recovered after the grazoprevir treatment stopped, showing the system’s potential to act as a safer alternative for patients than conventional CAR-T therapy. SNIP CAR-T cells also have improved efficacy in numerous models associated with more functional, less exhausted, and higher levels of memory CAR-T cells, which proved valuable in preserving healthy tissues.

Surprisingly, they also found that modulating grazoprevir dose made CAR-T cells attack cancer cells better, while avoiding normal tissues which express lower levels of the target molecule. The ability to design these cells to recognize target molecules co-occurring on healthy cells could transform the ability to tackle human solid tumors, reducing the previous “on-target off-tumor” toxicity effect.

However, determining the appropriate oral drug dose for a patient could be challenging due to variables caused by different T cell activity, tumor antigen expression, etc. Clinical studies will be the next step to establish the system’s possibilities in humans, particularly grazoprevir’s longer half-life in humans compared with mice.

©www.geneonline.com All rights reserved. Collaborate with us: service@geneonlineasia.com
Related Post
R&D
Revolutionizing Cancer Therapy: Insights from SK Life Science Labs Dr. Mohammad on p300 and SMARCA2 Targeted Protein Degradation Technologies
2024-03-07
FDA Boxed Warning for CAR-T therapy, Affecting Bristol-Myers Squibb, Novartis, Janssen, Gilead Sciences
2024-01-24
Novel Hydrogel Delivery System Could Reduce Daily Diabetes Injections to Three Times a Year
2023-12-04
LATEST
Innovating Cancer Treatment: The Role of ADC Technology at Nona Biosciences
2024-03-28
BIO CHINA 2024 Brings Biotech Experts and Industry Elites Together for Innovation
2024-03-27
Galderma’s Strong European IPO Debut
2024-03-26
Markets and Mergers: Boston Scientific and Axonics Shake Hands on Deal
2024-03-25
Discover the Next Billion-Dollar Unicorn at the Biotech Innovation Funding Networking Event
2024-03-21
AstraZeneca’s Latest Moves in Pharmaceuticals in Q1 2024
2024-03-21
AI-Designed Antibodies: A Revolution in Antibody Drug Discovery
2024-03-20
EVENT
2024-04-06
Biotech Innovation Funding Networking
Los Angeles, USA
Scroll to Top